Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date November 16, 2023 · Filed November 16, 2023
Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 10,305 |
Reported balance
Holding disclosure · report date 2023-11-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,305 F1: Ms. Blaise role change is not subject to reporting effective November, 16,2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Ms. Blaise role change is not subject to reporting effective November, 16,2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2023 Filed Nov 16, 2023 00:33 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 135.354 | $143.60 | $19,436.83 |
DisclosureSEC source: 0001127602-23-027461 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,305 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F2 · balance_after: Includes 85.032 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 21:56 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 379.689 | $165.67 | $62,903.08 |
DisclosureSEC source: 0001127602-23-023392 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,355 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 07/01/2022. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:08 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 3,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022931 · form4.xml · nonDerivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,735 F2 · kind: Represents performance-based restricted stock units granted on July 1, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:08 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 819 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022931 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,441 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:24 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 75 | $224.40 | $16,830.00 |
DisclosureSEC source: 0001127602-22-026264 · form4.xml · nonDerivative · entry 3 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,552 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:24 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 78 | $224.40 | $17,503.20 |
DisclosureSEC source: 0001127602-22-026264 · form4.xml · nonDerivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,627 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:24 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 114 | $224.40 | $25,581.60 |
DisclosureSEC source: 0001127602-22-026264 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,705 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 00:18 UTC Amendment | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 2,410 | $224.58 Strike: $224.58 | $541,237.80 |
DisclosureSEC source: 0001127602-22-026089 · form4a.xml · derivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410 Underlying: ResMed Common Stock · 2,410 shares Expires 2029-11-16 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 169 | $225.18 | $38,055.42 |
DisclosureSEC source: 0001127602-22-025844 · form4.xml · nonDerivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,335 F2 · balance_after: Includes 72.515 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 516 | $225.18 | $116,192.88 |
DisclosureSEC source: 0001127602-22-025844 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 15, 2022 Filed Nov 19, 2022 00:18 UTC Amendment | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 169 | $225.18 | $38,055.42 |
DisclosureSEC source: 0001127602-22-026089 · form4a.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 F1 · kind: Corrects transaction as disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/14/2018. F2 · balance_after: Reflects corrected share beneficially owned. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.